Number needed to treat associated with ixekizumab and etanercept from UNCOVER-2 and UNCOVER-3 Phase III trials in the treatment of moderate-to-severe psoriasis

被引：0
|
作者：
Foster, S. [1 ]
Zhu, B. [1 ]
Burge, R. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 05期
关键词：
D O I：
10.1016/j.jid.2016.02.177
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
150
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Egeberg, Alexander
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2101 - 2102
  • [42] Long-term efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis sustained for three years: Results of a randomized controlled phase 3 study (UNCOVER-3)
    Leonardi, Cathy L.
    Maari, Catherine
    Philipp, Sandra
    Crowley, Jeffrey
    Zhang, Lu
    Ball, Susan
    Mallbris, Lotus
    Gonzalez, Pablo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB180 - AB180
  • [43] Continued treatment with ixekizumab over 60 weeks provides sustained improvements in work productivity and activity levels: results from UNCOVER-2, a Phase 3 trial in patients with moderate-to-severe psoriasis
    Lynde, C.
    McBride, S.
    Stahle, M.
    Burge, R.
    Lin, C. -Y.
    Amato, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 69 - 70
  • [44] Ixekizumab sustains high efficacy and a favorable safety profile in burdensome areas in patients with moderate-to-severe psoriasis: 5-year results from UNCOVER-2
    Papp, Kim
    Blauvelt, Andrew
    Puig, Luis
    Elmaraghy, Hany
    See, Kyoungah
    McKean-Matthews, Missy
    Crane, Heidi
    Garrelts, Alyssa
    Leonardi, Craig
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB50 - AB50
  • [45] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Reply
    Gordon, Kenneth B.
    Colombel, Jean-Frederic
    Hardin, Dana S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2102 - 2102
  • [46] Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis
    Feldman, Steven R.
    Foster, Shonda A.
    Zhu, Baojin
    Burge, Russel
    Al Sawah, Sarah
    Goldblum, Orin M.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (12) : 1246 - 1252
  • [47] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3) (vol 77, pg 855, 2017)
    Blauvelt, A.
    Gooderham, M.
    Iversen, L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 301 - 301
  • [48] Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: Results through 108 weeks randomised, phase III clinical trial (UNCOVER-3)
    Blauvelt, A.
    Gooderham, M.
    Iversen, L.
    Ball, S.
    Zhang, L.
    Agada, N.
    Reich, K.
    Dossenbach, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
  • [49] Impact of ixekizumab treatment on scalp psoriasis: results from the placebo-controlled induction period of UNCOVER-3
    Reich, K.
    Leonardi, C.
    Lebwohl, M.
    Romiti, R.
    Goldblum, O.
    Zhang, L.
    Shrom, D.
    Dennehy, E.
    Sofen, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 73 - 73
  • [50] Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
    Papp, Kim
    Puig, Lluis
    Dutronc, Yves
    Kerr, Lisa
    Mallbris, Lotus
    Ilo, Dapo
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB257 - AB257
12345